ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Ube has agreed to acquire API Corp. from Mitsubishi Chemical for an undisclosed amount. Based in Tokyo, API is one of Japan’s largest drug contract development and manufacturing organizations, with several research and manufacturing sites in Japan and one in Brussels. Ube recently announced a reorganization under which it will operate as a holding company in markets including specialty and fine chemicals. The firm says it plans to expand beyond small-molecule drug manufacturing into nucleic acid drugs.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X